ComplianceOnline

483 sent to Jilin Shulan Synthetic Pharmaceutical Co.

  • By: Staff Editor
  • Source: www.fda.gov
Webinar All Access Pass Subscription Abstract:

Warning letter sent to Jilin Shulan Synthetic Pharmaceutical Co. regarding significant deviations from Current Good Manufacturing Practice (CGMP) for the manufacture of APIs.

Bookmark and Share

Trending Compliance Trainings

Cleaning Validation Swab Recovery Studies and Analysis
By - Keith Bader
On Demand Access Anytime
Transfer of Analytical Methods According to the USP Chapter <1224>
By - Dr. Ludwig Huber
On Demand Access Anytime
4-Hour Virtual Training: Auditing the Microbiology Laboratory
By - Robert D Seltzer
On Demand Access Anytime
Creating Effective SOPs for Regulatory Compliance
By - Henry Urbach
On Demand Access Anytime
Documentation Requirements for Master and Working Cell Banks
By - Debra Barngrover
On Demand Access Anytime
Quality Control for Microbiological Media and Reagents
By - Todd Graham
On Demand Access Anytime
Validation of Complex Cell-Based Potency Methods
By - Gwen Wise Blackman
On Demand Access Anytime
Best Sellers
You Recently Viewed
    Loading